The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

Hajime Maeda; Akira Kubota; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba; ASSET-K Study group

doi:10.1016/j.diabres.2011.10.011

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

Diabetes Res Clin Pract. 2012 Jan;95(1):e20-2. doi: 10.1016/j.diabres.2011.10.011. Epub 2011 Nov 3.

Authors

Hajime Maeda¹, Akira Kubota, Yasushi Tanaka, Yasuo Terauchi, Ikuro Matsuba; ASSET-K Study group

Collaborators

Affiliation

¹ The Study Group of the Diabetes Committee, Kanagawa Physicians Association, 3F Kanagawa-ken Sogo Iryo Kaikan, 3-1 Fujimi-cho, Naka-ward, Yokohama-city, Kanagawa 231-0037, Japan. hec@asahi-net.email.ne.jp

PMID: 22055835
DOI: 10.1016/j.diabres.2011.10.011

Abstract

We evaluated the efficacy and safety of sitagliptin after 3 months' treatment in Japanese type 2 diabetic patients and examined changes in clinical factors. Baseline HbA1c, PPG, BMI, and duration of diabetes may be predictors of HbA1c reduction when using sitagliptin in Japanese type 2 diabetic patients.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / adverse effects
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Female
Glycated Hemoglobin / metabolism*
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use
Japan
Male
Metformin / adverse effects
Metformin / therapeutic use
Middle Aged
Pyrazines / adverse effects
Pyrazines / therapeutic use*
Sitagliptin Phosphate
Treatment Outcome
Triazoles / adverse effects
Triazoles / therapeutic use*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Glycated Hemoglobin A
Hypoglycemic Agents
Pyrazines
Triazoles
Metformin
Sitagliptin Phosphate